Paclitaxel enhances macrophage IL-12 production in tumor-bearing hosts through nitric oxide

Journal of Immunology

Volumn 162, Issue 11, 1999, Pages 6811-6818

  Mullins, David W ^a,b   Burger, Carol J ^a   Elgert, Klaus D ^a  

^a VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY   (United States)

^b UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; INTERLEUKIN 12; LIPOPOLYSACCHARIDE; N(G) METHYLARGININE; NITRIC OXIDE; PACLITAXEL; PROTEIN P40;

ALLOIMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOCRINE EFFECT; CONTROLLED STUDY; CYTOKINE PRODUCTION; MACROPHAGE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DIMERIZATION; IMMUNE TOLERANCE; INTERLEUKIN-12; LYMPHOCYTE ACTIVATION; MACROPHAGES; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; NITRIC OXIDE; PACLITAXEL; SARCOMA, EXPERIMENTAL; T-LYMPHOCYTES;

EID: 0033152004     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (70)

1. Elgert, K. D., D. G. Alleva, and D. W. Mullins 1998. Tumor-induced immune dysfunction: the macrophage connection. J. Leukocyte Biol. 64:275.
2. Mullins, D. W., D. G. Alleva, C. J Burger, and K. D. Elgert. 1997. Taxol, a microtubule-stabilizing antineoplaslic agent, differentially regulates normal and tumor-bearing host macrophage nitric oxide production. Immunopharmacology 37:63.
3. Mullins, D. W., T. M. Walker, C. J. Burger, and K. D. Elgert. 1997. Taxol-mediated changes in fibrosarcoma-induced immune cell function: modulation of antitumor activities. Cancer Immunol. Immunother. 45:20.
4. Mullins, D. W., C. J. Burger, and K. D. Elgert. 1998. Tumor growth modulates macrophage nitric oxide production following paclitaxel administration. Int. J. Immunopharmacol. 20:537.
5. Kingston, D. G. I. 1991. The chemistry of taxol. Pharmacol. Ther. 52:1.
6. Donaldson, K. L., G. L. Goolsby, and A. F. Wahl. 1994. Cytoloxicity of the anticancer agents cisplatin and taxol during cell proliferation and the cell cycle. Int. J. Cancer 57:847.
7. Fuchs, D. A., and R. K. Johnson. 1978. Cytologic evidence that taxol, an antineoplastic agent from Taxus brevifolia, acts as a mitotic spindle poison. Cancer Treat. Rep. 62:1219.
8. Rowinsky, E. K., R. C. Donehower, R. J. Jones, and R. W. Tucker. 1988. Microtubule changes and cytotoxicity in leukemic cell lines treated with taxol. Cancer Res. 48:4093.
9. Hajek, R., J. Vorlicek, and M. Slavik. 1996. Paclitaxel (taxol): a review of its antitumor activity in clinical studies. Neoplasma 43:141.
10. Wiseman, L. R., and C. M. Spencer. 1998. Paclitaxel: an update of its use in the treatment of metastatic breast cancer and ovarian and other gynecological cancers. Drugs Aging. 12:305.
11. Schiff, P. B., J. Fant, and S. B. Horwitz. 1979. Promotion of microtubule assembly in vitro by taxol. Nature 22:665.
12. Milas, L., N. R. Hunter, K. A. Mason, B. Kurdoglu, and L. J. Peters. 1994. Enhancement of tumor radioresponse of a murine mammary carcinoma by paclitaxel. Cancer Res. 54:3506.
13. Williams, S., D. G. Mutch, L. Xu, and J. L. Collins. 1992. Divergent effects of taxol on tumor necrosis factor-α-mediated cylolysis of ovarian carcinoma cells. Am. J. Obstet. Gynecol. 167:1870.
14. Bottex-Gauthier, C., F. Condemine, F. Picot, and D. Vidal. 1992. Effects of taxol on the macrophage function: interactions with some immunological parameters. Immunopharmacol. Immunotoxicol. 14:39.
15. Vogel, S. N., C. L. Manthey, M. E. Brandes, P.-Y. Perera, and C. A. Salkowski. 1993. LPS mimetic effects of taxol on LPS-inducible gene expression, glucorticoid receptor expression, and tyrosine phosphorylation in murine macrophages. In Bacterial Endotoxin: Recognition and Effector Mechanisms. J. Levin, C. R. Alving, R. S. Munford, and P. L. Stutz, eds. Excerpta Medica, New York, p. 243.
16. Manthey, C. L., M. E. Brandes, P.-Y. Perera, and S. N. Vogel. 1992. Taxol increases steady-state levels of lipopolysaccharide-inducible genes and protein-tyrosine phosphorylation in murine macrophages. J. Immunol. 149:2459.
17. Manthey, C. L., P.-Y. Perera, C. A. Salkowski, and S. N. Vogel. 1994. Taxol provides a second signal for murine macrophage tumoricidal activity. J. Immunol. 152:825.
18. Ding, A. H., F. Porteu, E. Sanchez, and C. F. Nathan. 1990. Shared actions of endotoxin and taxol on TNF receptors and TNF release. Science 248:370.
19. Bogdan, C., and A. H. Ding. 1992. Taxol, a microtubule-stabilizing antineoplastic agent, induces expression of tumor necrosis factor-α and interleukin-1 in macrophages. J. Leukocyte Biol. 52:119.
20. Pae, H. O., C. D. Jun, J. C. Yoo, H. J. Kwak, S. J. Lee, Y. A. Kook, R. K. Park, and H. T. Chung. 1998. Enhancing and priming of macrophages for superoxide anion production by taxol. Immunopharmacol. Immunotoxicol. 20:27.
21. Hwang, S., and A. H. Ding. 1995. Activalion of NF-κΒ in murine macrophages by taxol. Cancer Biochem. Biophys. 14:265.
22. Hibbs, J. B., Jr., R. R. Taintor, Z. Vavrin, and E. M. Rachlin. 1988. Nitric oxide: a cytotoxic activated macrophage effector molecule. Biochem. Biophys. Res. Commun. 157:87.
23. Tahara, H., and M. T. Lotze. 1995. Antitumor effects of interleukin-12 (IL-12): applications for the immunotherapy and gene therapy of cancer. Gene Ther. 2:96.
24. Lotze, M. T., L. Zitvogel, R. Campbell, P. D. Robbins, E. Elder, C. Haluszczak, D. Martin, T. L. Whiteside, W. J. Storkus, and H. Tahara. 1996. Cytokine gene therapy of cancer using interleukin-12: murine and clinical trials. In Interleukin-12: Cellular and Molecular Immunology of an Important Regulatory Cytokine, 795th ed. M. T. Lotze, G. Trinchieri, M. Gately, and S. Wolf. eds. New York Academy of Sciences, New York, p. 440.
25. Frei, K., H. Lins, C. Schwerdel, and A. Fontana. 1994. Antigen presentation in the central nervous system: the inhibitory effect of IL-10 on MHC class II expression and production of cytokines depends on the inducing signals and the type of cell analyzed. J. Immunol. 152:2720.
26. Ding, A. H., E. Sanchez, and C. F. Nathan. 1993. Taxol shares the ability of bacterial lipopolysaccharide to induce tyrosine phosphorylation of microtubule-associated protein kinase. J. Immunol. 151:5596.
27. Carboni, J., C. Singh, and M. A. Tepper. 1993. Taxol and lipopolysaccharide activation of a murine macrophage cell line and induction of similar tyrosine phosphoproteins. Monogr. Natl. Cancer Inst. 15:95.
28. d, macrophages. Mol. Med. 1:428.
29. Elgert, K. D., and W. L. Farrar. 1978. Suppressor cell activity in tumor-bearing mice. I. Dualistic inhibition by suppressor T lymphocytes and macrophages. J. Immunol. 120:1345.
30. 2. J. Immunol. 153:1674.
31. Elgert, K. D., and K. M. Connolly. 1978. Macrophage regulation of the T cell allogeneic response during tumor growth. Cell. Immunol. 35:1.
32. Wysocka, M., M. Kubin, L. Q. Vieira, L. Ozmen, G. Garotta, P. Scott, and G. Trinchieri. 1995. Interleukin-12 is required for interferon-γ production and lethality in lipopolysaccharide-induced shock in mice. Eur. J. Immunol. 25:672.
33. Heide, K., and H. G. Schwies. 1973. Salt fractionation of immunoglobulins. In Handbook of Experimental Immunology. D. M. Weir, ed. Blackwell Scientific, Oxford, U.K., p. 6.1.
34. 15N]nitrate in biological fluids. Anal. Biochem. 126:131.
35. Ma, X., J. M. Chow, G. Gri, F. Gerosa, S. F. Wolf, R. Dzialo, and G. Trinchieri. 1996. The interleukin 12 p40 gene promoter is primed by interferon-γ in monocytic cells. J. Exp. Med. 183:147.
36. Ma, X., M. Aste-Amezaga, and G. Trinchieri. 1996. Regulation of interleukin-12 production. In Interleukin-12: Cellular and Molecular Immunology of an Important Regulatory Cytokine. 795th ed. M. T. Lotze, G. Trinchieri, M. Gately, and S. Wolf, eds. New York Academy of Sciences, New York, p. 13.
37. Hayes, M. P., I. Wang, and M. A. Norcross. 1995. Regulation of interleukin-12 expression in human monocytes: selective priming by interferon-γ of lipopolysaccharide-inducible p35 and p40 genes. Blood 86:646.
38. Rothe, H., B. Hartmann, P. Geerlings, and H. Kolb. 1996. Interleukin-12 geneexpression of macrophages is regulated by nitric oxide. Biochem. Biophys. Res. Commun. 224:159.
39. + macrophages from normal and tumor-bearing hosts: flow cytofluorometrically separated macrophages. Immunobiology 182:1.
40. Walker, T. M., A. D. Yurochko, C. J. Burger, and K. D. Elgert. 1992. Tumor growth changes the contribution of granulocyte-macrophage colony-stimulating factor during macrophage-mediated suppression of allorecognition. Immunobiology 185:427.
41. 2, Ia, and tumor necrosis factor-α. Immunopharmacology 25:215.
42. Kobayashi, M., L. Fitz, M. Ryan, R. M. Hewick, S. C. Clark, S. C. Chan, R. Loudon, F. Sherman, B. Perussia, and G. Trinchieri. 1989. Identification and purification of natural killer cell stimulatory factor (NKSF), a Cytokine with multiple biological effects on human lymphocytes. J. Exp. Med. 170:827.
43. Maruo, S., K. Toyo-oka, M. Oh-hora, X-G. Tai, H. Iwara, H. Takenaka, S. Yamada, S. Ono, T. Hamaoka, M. Kobayashi, M. Wysocka, G. Trinchieri, and H. Fujiwara. 1996. IL-12 produced by antigen-presenting cells induces IL-2-dependent proliferation of T helper cell clones. J. Immunol. 156:1748.
44. Mullins, D. W., M. D. Koci, C. J. Burger, and K. D. Elgert. 1998. Interleukin-12 overcomes paclitaxel-mediated suppression of T-cell proliferation. Immunopharmacol. Immunotoxicol. 20:473.
45. Trinchieri, G. 1998. Interleukin-12: a cytokine at the interface of inflammation and immunity. Adv. Immunol. 70:83.
46. Gately, M. K., R. R. Warrier, S. Honasoge, D. M. Carvajal, D. A. Faherty, S. E. Connaughton, T. D. Andersen, U. Sarmiento, B. R. Hubbard, and M. Murphy. 1994. Administration of recombinant IL-12 to normal mice enhances cytolytic lymphocyte activity and induces production of IFN-γ in vivo. Int. Immunol. 6:157.
47. + T lymphocytes. J. Immunol. 151:2444.
48. + T cells to enhance priming for interferon γ production and diminishes interleukin 4 inhibition of such priming. Proc. Natl. Acad. Sci. USA 90:10188.
49. Chan, S. H., B. Perussia, J. M. Gupta, M. Kobayashi, M. Pospisil, H. A. Young, S. F. Wolf, D. Young, S. C. Clark, and G. Trinchieri. 1991. Induction of interferon-7 production by natural killer cell stimulatory factor: characterization of the responding cells and synergy with other inducers. J. Exp. Med. 173:869.
50. Chan, S. H., M. Kobayashi, D. Santoli, B. Perussia, and G. Trinchieri. 1992. Mechanism of IFN-γ induction by natural killer cell stimulatory factor (NKSF/ IL-12): role of transcription and mRNA stability in the synergistic interactions between NKSF and IL-2. J. Immunol. 148:92.
51. Sieling, P. A., X.-H. Wang, M. K. Gately, J. L. Oliveros, T. McHugh, P. F. Barnes, S. F. Wolf, L. Golkar, M. Yamamura, Y. Yogi, K. Uyemura, T. H. Rea, and R. L. Modlin. 1994. IL-12 regulates T helper type 1 cytokine responses in human infectious disease. J. Immunol. 153:3639.
52. Yang, G., K. E. Hellstrom, I. Hellstrom, and L. Chen. 1995. Antitumor immunity elicited by tumor cells transfected with B7-2, a second ligand for CD28/CTLA-4 costimulatory molecules. J. Immunol. 154:2794.
53. + T cells. J. Immunol. 154:5071.
54. Wolf, S. F., D. Sieburth, and J. Sypek. 1994. Interleukin-12: a key modulator of immune function. Stem Cells 12:154.
55. Gately, M. K., U. Gubler, M. J. Brunda, R. R. Nadeau, T. D. Anderson, J. M. Lipman, and U. Sarmiento. 1994. Interteukin-12: a cytokine with therapeutic potential in oncology and infectious diseases. Ther. Immunol. 1:187.
56. Zeh, H. J., III, S. Hurd, III, W. J. Storkus, and M. T. Lotze. 1993. Interleukin-12 promotes proliferation and cytolytic maturation of immune effectors: implications for immunotherapy of cancer. J. Immunother. 14:155.
57. Nastala, C. L., H. D. Edington, T. G. McKinney, H. Tahara, M. A. Nalesnik, M. J. Brunda, M. K. Gately, S. F. Wolf, R. D. Schreiber, W. J. Storkus, and M. T. Lotze. 1994. Recombinant IL-12 administration induces tumor regression in association with IFN-γ production. J. Immunol. 153:1697.
58. Tahara, H., L. Zitvogel, W. J. Storkus, H. J. Zeh, III, T. G. McKinney, R. D. Schreiber, U. Gubler, P. D. Robbins, and M. T. Lotze. 1995. Effective eradication of established murine tumors with IL-12 gene therapy using polycistronic retroviral vector. J. Immunol. 154:6466.
59. Zitvogel, L., H. Tahara, P. D. Robbins, W. J. Storkus, M. R. Clarke, M. A. Nalesnik, and M. T. Lotze. 1995. Cancer immunotherapy of established tumors with IL-12: effective delivery by genetically engineered fibroblasts. J. Immunol. 155:1393.
60. Lucey, D. R., M. Clerici, and G. M. Shearer. 1996. Type 1 and type 2 cytokine dysregulation in human infectious, neoplastic, and inflammatory diseases. Clin. Microbiol. Rev. 9:532.
61. Handel-Fernandez, M. E., X. Cheng, L. M. Herbert, and D. M. Lopez. 1997. Down-regulation of IL-12, not a shift from T helper-1 to T helper-2 phenotype, is responsible for impaired IFN-γ production in mammary tumor-bearing mice. J. Immunol. 158:280.
62. Schwacha, M. G., and T. K. Eisenstein. 1997. Interleukin-12 is critical for induction of nitric oxide-mediated immunosuppression following vaccination of mice with attenuated Salmonella typhimurium. Infect. Immun. 65:4897.
63. Wigginton, J. M., D. B. Kuhns, T. C. Back, M. J. Brunda, R. H. Wiltrout, and G. W. Cox. 1996. Interleukin 12 primes macrophages for nitric oxide production in vivo and restores depressed nitric oxide production by macrophages from tumor bearing mice: implications for the antitumor activity of interleukin 12 and/or interleukin 2. Cancer Res. 56:1131.
64. Albina, J. E., J. A. Abate, and W. L. Henry, Jr. 1991. Nitric oxide production is required for murine resident peritoneal macrophages to suppress mitogen-stimulated T cell proliferation: role of IFN-γ in the induction of the nitric oxide-synthesizing pathway. J. Immunol. 147:144.
65. Gregory, S. H., A. J. Sagnimeni, and E. J. Wing. 1994. Arginine analogues suppress antigen-specific and -nonspecific T lymphocyte proliferation. Cell. Immunol. 153:527.
66. Young, M. R., M. A. Wright, J. P. Matthews, I. Malik, and M. Prechel. 1996. Suppression of T cell proliferation by tumor-induced granulocyte-macrophage progenitor cells producing transforming growth factor-β and nitric oxide. J. Immunol. 156:1916.
67. Hunter, S. E., K. E. Waldburger, D. K. Thibodeaux, R. G. Schaub, S. J. Goldman, and J. P. Leonard. 1997. Immunoregulation by interleukin-12 in MB49.1 tumor-bearing mice: cellular and cytokine-mediated effector mechanisms. Eur. J. Immunol. 27:3438.
68. Denis, M. 1994. Human monocytes/macrophages: NO or no NO? J. Leukocyte Biol. 55:682.
69. Weinberg, J. B., M. A. Misukonis, P. J. Shami, S. N. Mason, D. L. Sauls, W. A. Dittman, E. R. Wood, G. K. Smith, B. McDonald, K. E. Bachus, A. F. Haney, and D. L. Granger. 1995. Human mononuclear phagocyte inducible nitric oxide synthase (iNOS): analysis of iNOS mRNA, iNOS protein, biopterin, and nitric oxide production by blood monocytes and peritoneal macrophages. Blood 86:1184.
70. Dugas, B., M. D. Mossalayi, C. Damais, and J.-P. Kolb. 1995. Nitric oxide production by human monocytes: evidence for role of CD23. Immunol. Today 16: 574.